Rhythm Pharmaceuticals, Inc.
RYTM
$90.51
$3.133.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 45.83% | 54.92% | 53.55% | 48.88% | 68.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.83% | 54.92% | 53.55% | 48.88% | 68.06% |
| Cost of Revenue | 45.80% | 44.18% | 47.43% | 32.95% | 43.72% |
| Gross Profit | 45.83% | 56.30% | 54.32% | 50.98% | 71.38% |
| SG&A Expenses | 35.09% | 26.74% | 18.63% | 17.07% | 22.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.08% | -6.13% | -12.23% | -19.96% | -19.46% |
| Operating Income | -137.92% | 45.81% | 50.90% | 55.26% | 56.22% |
| Income Before Tax | 24.66% | 25.70% | 29.06% | 38.26% | -41.34% |
| Income Tax Expenses | 44.06% | -30.59% | -101.27% | -85.53% | -38.83% |
| Earnings from Continuing Operations | 24.57% | 25.72% | 29.44% | 38.40% | -41.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.57% | 25.72% | 29.44% | 38.40% | -41.09% |
| EBIT | -137.92% | 45.81% | 50.90% | 55.26% | 56.22% |
| EBITDA | -140.93% | 46.15% | 51.31% | 55.70% | 56.66% |
| EPS Basic | 28.70% | 28.47% | 30.88% | 39.30% | -35.92% |
| Normalized Basic EPS | -115.80% | 47.77% | 51.13% | 55.53% | 56.27% |
| EPS Diluted | 28.70% | 28.47% | 30.88% | 39.30% | -35.92% |
| Normalized Diluted EPS | -115.80% | 47.77% | 51.13% | 55.53% | 56.27% |
| Average Basic Shares Outstanding | 6.52% | 5.39% | 4.75% | 5.46% | 5.77% |
| Average Diluted Shares Outstanding | 6.52% | 5.39% | 4.75% | 5.46% | 5.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |